ESPR vs SNY
Esperion Therapeutics Inc (ESPR) versus SNY (SNY) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
SNY (SNY) common stock.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
SNY does not have a complete income-statement cache yet.
ESPR currently screens at market cap $816.9M. SNY currently screens at market cap $0.
Not investment advice. Open the ESPR and SNY stock pages for the full models.
Not investment advice.